Isis Pharmaceuticals, Inc. announced that the company expects to significantly improve upon its 2014 financial guidance. The company expects to end 2014 with a pro forma net operating loss in the mid to high teens and more than $725 million in cash. The significantly improved financial performance of the company in 2014 was a result of the successful execution of its business strategy, the maturation of its pipeline and the growing validation of antisense as a viable, efficient and effective drug discovery technology.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
49.84 USD | +4.77% |
|
+5.95% | -1.48% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.48% | 7.27B | |
+25.83% | 47.96B | |
+45.38% | 41.47B | |
+0.69% | 42.45B | |
+30.52% | 31.6B | |
+22.30% | 28.63B | |
-6.35% | 28.03B | |
+49.25% | 14.56B | |
+49.18% | 14.14B | |
+3.45% | 12.58B |
- Stock Market
- Equities
- IONS Stock
- News Ionis Pharmaceuticals, Inc.
- Isis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2014